Coreo AG — Board/Management Information 2009

Jul 27, 2009

News Details

Corporate | 27 July 2009 07:30

Prof. Alex Matter becomes member of the Board of Directors of Nanostart holding Curiox Biosystems

Nanostart AG / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

• Scientist of international reputation
• Former Head of Oncology Research at Novartis
• 'Curiox establishes itself'

Frankfurt / Singapore - July 27, 2009 - Prof. Dr. Alex Matter has joined
the Board of Directors of Singaporean Nanostart holding Curiox Biosystems.
Dr. Matter is best known for his contribution to the development of
Glivec/Gleevec(R), one of the world's first tyrosine kinase inhibitor drugs
against chronic myeloid leukemia (CML). Starting in the mid-eighties, Dr.
Matter led a team of close to 200 scientists at Novartis to discover and
optimize the lead compound and brought it all the way through its first
clinical trial in 1998. In a short span of 3 years, Glivec/Gleevec(R) was
given a very rare, fast track FDA approval in 2001.

He was the founding director of the Novartis Institute for Tropical
Diseases and is Chief Executive Officer of the Experimental Therapeutics
Centre (ETC), both located in Singapore. During his long career in the
pharmaceutical industry Dr. Matter has held several positions of
responsibility such as Head of Pharmaceutical Research at Hoffman-LaRoche,
Head of Cancer and Viral Research at CIBA-GEIGY and more recently Global
Head of Oncology Research, at Novartis Pharmaceuticals Corporation. Dr.
Alex Matter, received his medical degree from the University of Basel. He
has authored over 100 scientific articles and book chapters in the areas of
oncology and hematology. He is the recipient of the 13th Warren-Alpert
prize in 2000 and the AACR-Bruce F. Cain Memorial Award.

Matter comments his service in the Board of Directors of Curiox: 'I am
looking forward to work with Curiox which pursues innovative, cutting-edge
technologies in the field of high throughput screening and establishes
itself in a rapidly growing hightech market segment.'

Namyong Kim, CEO of Curiox, believes that Matter's huge experience and
network will assure the success of new DropArray(TM) products that are
going to be launched in the next few months for the pharmaceutical and
biotech market. Kim says: 'The ready acceptance of the invitation by Dr.
Matter in joining the Board shows the strength and promise of Curiox's
unique DropArray(TM) technology in innovating the ways of preclinical drug
discovery are performed. I look forward to working with him in building
Curiox into one of major bioinstrumentation companies.'

About Nanostart:
Nanostart AG is the world's leading nanotechnology investment company. The
Frankfurt-based company provides venture capital financing for
nanotechnology companies in various growth phases. It also provides the
benefits of its experience and expertise to developers of financial
instruments and to investors in the nanotechnology sector. For further
information about the company, please visit www.nanostart.de.

About Curiox Biosystems Pte. Ltd.
Curiox Biosystems has a vision to accelerate the progress of life sciences
and drug discovery through better miniaturization. Curiox is a
bioinstrumentation company enabling the miniaturization of heterogeneous
bioassay for researchers working in life sciences, drug discovery, and
diagnostics. Curiox's patented miniaturization platform, DropArray(TM),
provides up to 1,000 times savings in sample and reagent consumption, and
up to 10 times reduction in assay time. The company is located at Biopolis
in Singapore, the biomedical hub of Singapore and Southeast Asia. The
company is a spin-off from Institute of Bioengineering and Nanotechnology
(IBN) backed primarily by Nanostart and Exploit Technologies, the
commercializing arm of Singapore's Agency for Science, Technology and
Research (A*STAR). For further information, please visit www.curiox.com.

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of
offers to purchase or subscribe to securities. There will be no public
offering of securities of Nanostart AG in conjunction with the existing
listing of its shares in the 'Entry Standard' segment of the regulated
unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This
notice does not constitute a securities prospectus. Neither this notice nor
the information contained within is intended for direct or indirect
distribution within the United States of America, Canada, Australia or
Japan.

Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail: presse@nanostart.de

27.07.2009 Financial News transmitted by DGAP